Examination of Trends in Non-Small Cell Lung Cancer Patients' Medical Study Experiences

NCT05778045 | Not Yet Recruiting

• 1 other identifier: 87324981
• Study Type: observational
• Target: 500
• Locations: 0 countries
• Sites: N/A

Brief Summary

Medical study participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. Participating in an observational clinical trial may help patients with non-small cell lung cancer since it advances medical knowledge and may improve treatment choices in the future.

Conditions

Non-Small Cell Lung Cancer

Keywords

non-small cell lung cancer

Outcome Measures

Primary Outcomes (2)

• Rate of patients who decide to enroll in a non-small cell lung cancer clinical study.

  3 months

• Number of non-small cell lung cancer patients who remain in clinical trial until completion.

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Non-small cell lung cancer patients who are actively considering involvement in an observational clinical trial, but have not yet completed enrollment and registration.

You may qualify if:

• Participant has a diagnosis of non-small cell lung cancer
• Patient has self-identified as planning to enroll in a clinical trial for non-small cell lung cancer
• Patient is at least 18 years of age

You may not qualify if:

• Inability to perform regular electronic reporting
• Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial
• Pregnant or lactating woman

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Related Publications (3)

• Kayser G. [Non-small cell lung cancer. New biomarkers for diagnostics and therapy]. Pathologe. 2015 Nov;36 Suppl 2:189-93. doi: 10.1007/s00292-015-0084-1. German.

  PMID: 26391246 BACKGROUND

• Dufraing K, Van Casteren K, Breyne J, D'Haene N, Van Campenhout C, Vander Borght S, Zwaenepoel K, Rouleau E, Schuuring E, von der Thusen J, Dequeker E. Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders. BMC Cancer. 2022 Jul 6;22(1):736. doi: 10.1186/s12885-022-09798-5.

  PMID: 35794532 BACKGROUND

• Simeone JC, Nordstrom BL, Patel K, Klein AB. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting. Future Oncol. 2019 Oct;15(30):3491-3502. doi: 10.2217/fon-2019-0348. Epub 2019 Sep 9.

  PMID: 31497994 BACKGROUND

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Michael B Gill

  Power Life Sciences Inc.

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

415-900-4227; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 10, 2023
• First Posted: March 21, 2023
• Study Start: April 1, 2024
• Primary Completion: May 1, 2025
• Study Completion (Estimated): June 1, 2026
• Last Updated: March 21, 2023

Record last verified: 2023-03